Document:

Exhibit 10.9

 

Warrant Certificate No. ______

 

NEITHER THE SECURITIES REPRESENTED HEREBY
NOR THE SECURITIES ISSUABLE UPON THE EXERCISE OF THIS WARRANT HAVE BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933,
AS AMENDED (THE “SECURITIES ACT”) OR ANY STATE SECURITIES LAWS. SUCH SECURITIES MAY BE OFFERED, SOLD, PLEDGED
OR OTHERWISE TRANSFERRED ONLY (A) TO THE COMPANY, (B) IN COMPLIANCE WITH RULE 144 UNDER THE SECURITIES ACT, IF AVAILABLE, AND IN
ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS, (C) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT, OR (D) IN A TRANSACTION
THAT DOES NOT REQUIRE REGISTRATION UNDER THE SECURITIES ACT OR ANY APPLICABLE STATE SECURITIES LAWS, AND THE HOLDER HAS, PRIOR
TO SUCH SALE, FURNISHED TO THE COMPANY AN OPINION OF COUNSEL OR OTHER EVIDENCE OF EXEMPTION, IN EITHER CASE REASONABLY SATISFACTORY
TO THE COMPANY. HEDGING TRANSACTIONS INVOLVING THESE SECURITIES MAY NOT BE CONDUCTED UNLESS IN COMPLIANCE WITH THE SECURITIES ACT.

  

	Effective Date: _________, 2014	Expiration Date: __________, 2019

 

EKSO BIONICS HOLDINGS, INC.

 

WARRANT TO PURCHASE COMMON STOCK

 

Ekso Bionics Holdings,
Inc., a Nevada corporation (the “Company”), for value received on the Effective Date, hereby issues to __________________________
(the “Holder”) this Warrant (the “Warrant”) to purchase ______________ shares (as from time
to time adjusted as hereinafter provided) (each such share a “Warrant Share” and all such shares being the “Warrant
Shares”) of the Company’s Common Stock (as defined below), at the Exercise Price (as defined below), as adjusted
from time to time as provided herein, on or before the Expiration Date, all subject to the following terms and conditions.

 

This Warrant is one
of a series of Warrants of like tenor being issued to Subscribers in the Company’s private offering (the “Offering”)
of Units of its securities in accordance with, and subject to, the terms and conditions described in the Subscription Agreement
entered into by and between the Company and each Subscriber set forth on the signature pages affixed thereto (the “Subscription
Agreement”). Capitalized terms used herein without definition have the meanings ascribed to them in the Subscription
Agreement.

 

As used in this Warrant,
(i) “Business Day” means any day other than Saturday, Sunday or any other day on which commercial banks in the
City of New York, New York, are authorized or required by law or executive order to close; (ii) “Common Stock”
means the common stock of the Company, $0.001 par value per share, including any securities issued or issuable with respect thereto
or into which or for which such shares may be exchanged for, or converted into, pursuant to any stock dividend, stock split, stock
combination, recapitalization, reclassification, reorganization or other similar event; (iii) “Exercise Price”
means $1.00 per share of Common Stock, subject to adjustment as provided herein; (iv) “Trading Day” means any
day on which the primary national or regional stock exchange on which the Common Stock is listed, or if not so listed, the OTC
Bulletin Board or the OTC Markets, if quoted thereon, is open for the transaction of business;
and (v) “Affiliate” means any person that, directly or indirectly, through one or more intermediaries, controls,
is controlled by, or is under common control with, a person, as such terms are used and construed in Rule 144 promulgated under
the Securities Act of 1933, as amended (the “Securities Act”).

 

    	 

    	 

    

 

1.          DURATION
AND EXERCISE OF WARRANTS

 

(a)          Exercise
Period. The Holder may exercise this Warrant in whole or in part on any Business Day on or before 5:00 P.M., Eastern Time,
on the Expiration Date, at which time this Warrant shall become void and of no value.

 

(b)          Exercise
Procedures.

 

(i)          While
this Warrant remains outstanding and exercisable in accordance with Section 1(a), the Holder may exercise this Warrant in whole
or in part at any time and from time to time by:

 

(A)         delivery
to the Company of a duly completed and executed copy of the notice of exercise attached as Exhibit A (the “Notice
of Exercise”);

 

(B)         surrender
of this Warrant to the Secretary of the Company at its principal offices or at such other office or agency as the Company may specify
in writing to the Holder; and

 

(C)         payment
of the then-applicable Exercise Price per share multiplied by the number of Warrant Shares being purchased upon exercise of the
Warrant (such amount, the “Aggregate Exercise Price”) made in the form of cash, or by certified check, wire
transfer, bank draft or money order payable in lawful money of the United States of America.

 

(ii)         Upon
the exercise of this Warrant in compliance with the provisions of this Section 1(b), and except as limited pursuant to Section
1(b)(iii), the Company shall promptly issue and cause to be delivered to the Holder a certificate for the Warrant Shares purchased
by the Holder. Each exercise of this Warrant shall be effective immediately prior to the close of business on the date (the “Date
of Exercise”) that the conditions set forth in Section 1(b) have been satisfied, as the case may be. Upon delivery of
each of the items set forth in Section 1(b)(i), the Holder shall be deemed for all corporate purposes to have become the holder
of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of
the certificates evidencing such Warrant Shares.

 

    	2

    	 

    

 

(iii)        Notwithstanding
the foregoing provisions of this Section 1(b), the Holder may not exercise this Warrant if and to the extent that such exercise
would require the Company to issue a number of shares of Common Stock in excess of its authorized but unissued shares of Common
Stock, less all amounts of Common Stock that have been reserved for issue upon the conversion of all outstanding securities convertible
into shares of Common Stock and the exercise of all outstanding options, warrants and other rights exercisable for shares of Common
Stock. If the Company does not have the requisite number of authorized but unissued shares of Common Stock to permit the Holder
to exercise this Warrant, then the Company shall use commercially reasonable efforts to obtain the necessary stockholder consent
to increase the authorized number of shares of Common Stock to permit such Holder to exercise this Warrant pursuant to Section
1(b)(i).

 

(c)          Partial
Exercise. This Warrant shall be exercisable, either in its entirety or, from time to time, for part only of the number of Warrant
Shares referenced by this Warrant; provided, that any such partial exercise must be for an integral number of Warrant Shares. If
this Warrant is exercised in part, the Company shall issue, at its expense, a new Warrant, in substantially the form of this Warrant,
referencing such reduced number of Warrant Shares that remain subject to this Warrant.

 

(e)          Disputes.
In the case of a dispute as to the determination of the Exercise Price or the arithmetic calculation of the Warrant Shares, the
Company shall promptly issue to the Holder the number of Warrant Shares that are not disputed and resolve such dispute in accordance
with Section 15.

 

2.          ISSUANCE
OF WARRANT SHARES

 

(a)          The
Company covenants that all Warrant Shares will, upon issuance in accordance with the terms of this Warrant, be (i) duly authorized,
fully paid and non-assessable, and (ii) free from all liens, charges and security interests, with the exception of claims arising
through the acts or omissions of any Holder and except as arising from applicable Federal and state securities laws.

 

(b)          The
Company shall register this Warrant upon records to be maintained by the Company for that purpose in the name of the record holder
of such Warrant from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner thereof
for the purpose of any exercise thereof, any distribution to the Holder thereof and for all other purposes.

 

(c)          The
Company will not, by amendment of its articles of incorporation, by-laws or through any reorganization, transfer of assets, consolidation,
merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance
of any of the terms to be observed or performed hereunder by the Company, but will at all times in good faith assist in the carrying
out of all the provisions of this Warrant and in the taking of all action necessary or appropriate in order to protect the rights
of the Holder to exercise this Warrant, or against impairment of such rights.

 

    	3

    	 

    

 

3.          ADJUSTMENTS
OF EXERCISE PRICE, NUMBER AND TYPE OF WARRANT SHARES

 

(a)          General.
The Exercise Price and the number of shares purchasable upon the exercise of this Warrant shall be subject to adjustment from time
to time upon the occurrence of certain events described in this Section 3(a); provided, that notwithstanding the provisions
of this Section 3, the Company shall not be required to make any adjustment if and to the extent that such adjustment would require
the Company to issue a number of shares of Common Stock in excess of its authorized but unissued shares of Common Stock, less all
amounts of Common Stock that have been reserved for issue upon the conversion of all outstanding securities convertible into shares
of Common Stock and the exercise of all outstanding options, warrants and other rights exercisable for shares of Common Stock.
If the Company does not have the requisite number of authorized but unissued shares of Common Stock to make any adjustment, the
Company shall use its commercially reasonable efforts to obtain the necessary stockholder consent to increase the authorized number
of shares of Common Stock to make such an adjustment pursuant to this Section 3(a).

 

(i)          Subdivision
or Combination of Stock. In case the Company shall at any time subdivide (whether by way of stock dividend, stock split or
otherwise) its outstanding shares of Common Stock into a greater number of shares, the Exercise Price in effect immediately prior
to such subdivision shall be proportionately reduced and the number of Warrant Shares shall be proportionately increased, and conversely,
in case the outstanding shares of Common Stock of the Company shall be combined (whether by way of stock combination, reverse stock
split or otherwise) into a smaller number of shares, the Exercise Price in effect immediately prior to such combination shall be
proportionately increased and the number of Warrant Shares shall be proportionately decreased. The Exercise Price and the Warrant
Shares, as so adjusted, shall be readjusted in the same manner upon the happening of any successive event or events described in
this Section 3(a)(i).

 

(ii)         Dividends
in Stock, Property, Reclassification. If at any time, or from time to time, the holders of Common Stock (or any shares of stock
or other securities at the time receivable upon the exercise of this Warrant) shall have received or become entitled to receive,
without payment therefor:

 

(A)         any
shares of stock or other securities that are at any time directly or indirectly convertible into or exchangeable for Common Stock,
or any rights or options to subscribe for, purchase or otherwise acquire any of the foregoing by way of dividend or other distribution,
or

 

(B)         additional
stock or other securities or property (including cash) by way of spin-off, split-up, reclassification, combination of shares or
similar corporate rearrangement (other than shares of Common Stock issued as a stock split or adjustments in respect of which shall
be covered by the terms of Section 3(a)(i) above),

 

    	4

    	 

    

 

then and in each such case, the Exercise
Price and the number of Warrant Shares to be obtained upon exercise of this Warrant shall be adjusted proportionately, and the
Holder hereof shall, upon the exercise of this Warrant, be entitled to receive, in addition to the number of shares of Common Stock
receivable thereupon, and without payment of any additional consideration therefor, the amount of stock and other securities and
property (including cash in the cases referred to above) that such Holder would hold on the date of such exercise had such Holder
been the holder of record of such Common Stock as of the date on which holders of Common Stock received or became entitled to receive
such shares or all other additional stock and other securities and property. The Exercise Price and the Warrant Shares, as so adjusted,
shall be readjusted in the same manner upon the happening of any successive event or events described in this Section 3(a)(ii).

 

(iii)        Reorganization,
Reclassification, Consolidation, Merger or Sale. If any recapitalization, reclassification or reorganization of the capital
stock of the Company, or any consolidation or merger of the Company with another corporation, or the sale of all or substantially
all of its assets or other transaction shall be effected in such a way that holders of Common Stock shall be entitled to receive
stock, securities or other assets or property (an “Organic Change”), then lawful and adequate provisions shall
be made by the Company whereby the Holder hereof shall thereafter have the right to purchase and receive (in lieu of the shares
of the Common Stock of the Company immediately theretofore purchasable and receivable upon the exercise of the rights represented
by this Warrant) such shares of stock, securities or other assets or property as may be issued or payable with respect to or in
exchange for a number of outstanding shares of such Common Stock equal to the number of shares of such stock immediately theretofore
purchasable and receivable assuming the full exercise of the rights represented by this Warrant. In the event of any Organic Change,
appropriate provision shall be made by the Company with respect to the rights and interests of the Holder of this Warrant to the
end that the provisions hereof (including, without limitation, provisions for adjustments of the Exercise Price and of the number
of shares purchasable and receivable upon the exercise of this Warrant) shall thereafter be applicable, in relation to any shares
of stock, securities or assets thereafter deliverable upon the exercise hereof. To the extent necessary to effect the foregoing
provisions, the successor corporation (if other than the Company) resulting from such consolidation or merger or the corporation
purchasing such assets shall assume by written instrument reasonably satisfactory in form and substance to the Holder executed
and mailed or delivered to the registered Holder hereof at the last address of such Holder appearing on the books of the Company,
the obligation to deliver to such Holder such shares of stock, securities or assets as, in accordance with the foregoing provisions,
such Holder may be entitled to purchase. If there is an Organic Change, then the
Company shall cause to be mailed to the Holder at its last address as it shall appear on the books and records of the Company,
at least 10 calendar days before the effective date of the Organic Change, a notice stating the date on which such Organic Change
is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall
be entitled to exchange their shares for securities, cash, or other property delivered upon such Organic Change; provided,
that the failure to mail such notice or any defect therein or in the mailing thereof shall not affect the validity of the corporate
action required to be specified in such notice. The Holder is entitled to exercise this Warrant during the 10-day period commencing
on the date of such notice to the effective date of the event triggering such notice. In any event, the successor corporation (if
other than the Company) resulting from such consolidation or merger or the corporation purchasing such assets shall be deemed to
assume such obligation to deliver to such Holder such shares of stock, securities or assets even in the absence of a written instrument
assuming such obligation to the extent such assumption occurs by operation of law.

 

    	5

    	 

    

 

(b)          Adjustment
of Exercise Price upon Issuance of Additional Shares of Common Stock. In the event the Company shall at any time prior to the
Expiration Date issue Additional Shares of Common Stock, as defined below, without consideration or for a consideration per share
less than the Exercise Price in effect immediately prior to such issue, then the Exercise Price shall be reduced, concurrently
with such issue, to a price (calculated to the nearest cent) determined by multiplying such Exercise Price by a fraction, (A) the
numerator of which shall be (1) the number of shares of Common Stock outstanding immediately prior to such issue plus (2) the number
of shares of Common Stock which the aggregate consideration received or to be received by the Company for the total number of Additional
Shares of Common Stock so issued would purchase at such Exercise Price; and (B) the denominator of which shall be the number of
shares of Common Stock outstanding immediately prior to such issue plus the number of such Additional Shares of Common Stock so
issued; provided that, (i) for the purpose of this Section 3(b), all shares of Common Stock issuable upon conversion or
exchange of convertible securities outstanding immediately prior to such issue shall be deemed to be outstanding, and (ii) the
number of shares of Common Stock deemed issuable upon conversion or exchange of such outstanding convertible securities shall be
determined without giving effect to any adjustments to the conversion or exchange price or conversion or exchange rate of such
convertible securities resulting from the issuance of Additional Shares of Common Stock that is the subject of this calculation.
For purposes of this Warrant, “Additional Shares of Common Stock” shall mean all shares of Common Stock issued
by the Company after the Effective Date (including without limitation any shares of Common Stock issuable upon conversion or exchange
of any convertible securities or upon exercise of any option or warrant, on an as-converted basis), other than: (i) shares
of Common Stock issued or issuable upon conversion or exchange of any convertible securities or exercise of any options outstanding
on the Effective Date after giving effect to the Merger and the conversion of the Bridge Notes; (ii) shares of Common Stock issued
or issuable upon conversion of the Warrants, the Bridge Warrants, the Placement Agent Warrants or the Bridge Placement Agent Warrants;
(iii) shares of Common Stock issued or issuable by reason of a dividend, stock split, split-up or other distribution on shares
of Common Stock that is covered by Sections 3(a)(i) through 3(a)(iii) above; (iv) shares of Common Stock issued in a registered
public offering under the Securities Act; (v) shares of Common Stock issued or issuable pursuant to the acquisition of another
entity or business by the Company by merger, purchase of substantially all of the assets or other reorganization or pursuant to
a joint venture agreement, but not including a transaction in which the Company is issuing securities primarily for the purpose
of raising capital or to an entity whose primary business is investing in securities; (vi) shares of Common Stock issued or
issuable to officers, directors and employees of, or consultants to, the Company pursuant to stock grants, option plans, purchase
plans or other employee stock incentive programs or arrangements approved by the Board of Directors, or upon exercise of options
or warrants granted to such parties pursuant to any such plan or arrangement; (vii) any securities issued or issuable by the Company
pursuant to the Subscription Agreement or upon conversion of the Bridge Notes; and (viii) securities issued to financial institutions,
institutional investors or lessors in connection with credit arrangements, equipment financings, lease arrangements or similar
transactions, in each case approved by a majority of disinterested directors of the Company, and in the aggregate not exceeding
ten percent (10%) of the number of shares of Common Stock outstanding at any time. The provisions of this Section 3(b) shall
not operate to increase the Exercise Price.

 

    	6

    	 

    

 

Upon each adjustment
of the Exercise Price pursuant to the provisions of this Section 3(b), the number of Warrant Shares issuable upon exercise of this
Warrant shall be adjusted by multiplying a number equal to the Exercise Price in effect immediately prior to such adjustment by
the number of Warrant Shares issuable upon exercise of this Warrant immediately prior to such adjustment and dividing the product
so obtained by the adjusted Exercise Price.

 

(c)          Certificate
as to Adjustments. Upon the occurrence of each adjustment or readjustment pursuant to this Section 3, the Company at its expense
shall promptly compute such adjustment or readjustment in accordance with the terms hereof and furnish to each Holder of this Warrant
a certificate setting forth such adjustment or readjustment and showing in detail the facts upon which such adjustment or readjustment
is based. The Company shall promptly furnish or cause to be furnished to such Holder a like certificate setting forth: (i) such
adjustments and readjustments; and (ii) the number of shares and the amount, if any, of other property which at the time would
be received upon the exercise of the Warrant.

 

(d)          Certain
Events. If any event occurs as to which the other provisions of this Section 3 are not strictly applicable but the lack of
any adjustment would not fairly protect the purchase rights of the Holder under this Warrant in accordance with the basic intent
and principles of such provisions, or if strictly applicable would not fairly protect the purchase rights of the Holder under this
Warrant in accordance with the basic intent and principles of such provisions, then the Company's Board of Directors will, in good
faith and subject to applicable law, make an appropriate adjustment to protect the rights of the Holder; provided, that
no such adjustment pursuant to this Section 3(d) will increase the Exercise Price or decrease the number of Warrant Shares as otherwise
determined pursuant to this Section 3.

 

4.          TRANSFERS
AND EXCHANGES OF WARRANT AND WARRANT SHARES

 

(a)          Registration
of Transfers and Exchanges. Subject to Section 4(c), upon the Holder’s surrender of this Warrant, with a duly executed
copy of the Form of Assignment attached as Exhibit B, to the Secretary of the Company at its principal offices or at such
other office or agency as the Company may specify in writing to the Holder, the Company shall register the transfer of all or any
portion of this Warrant. Upon such registration of transfer, the Company shall issue a new Warrant, in substantially the form of
this Warrant, evidencing the acquisition rights transferred to the transferee and a new Warrant, in similar form, evidencing the
remaining acquisition rights not transferred, to the Holder requesting the transfer.

 

(b)          Warrant
Exchangeable for Different Denominations. The Holder may exchange this Warrant for a new Warrant or Warrants, in substantially
the form of this Warrant, evidencing in the aggregate the right to purchase the number of Warrant Shares, which may then be purchased
hereunder, each of such new Warrants to be dated the date of such exchange and to represent the right to purchase such number of
Warrant Shares as shall be designated by the Holder. The Holder shall surrender this Warrant with duly executed instructions regarding
such re-certification of this Warrant to the Secretary of the Company at its principal offices or at such other office or agency
as the Company may specify in writing to the Holder.

 

 

    	7

    	 

    

 

(c)          Restrictions
on Transfers. This Warrant may not be transferred at any time without (i) registration under the Securities Act or (ii) an
exemption from such registration and a written opinion of legal counsel addressed to the Company that the proposed transfer of
the Warrant may be effected without registration under the Securities Act, which opinion will be in form and from counsel reasonably
satisfactory to the Company.

 

(d)          Permitted
Transfers and Assignments. Notwithstanding any provision to the contrary in this Section 4, the Holder may transfer, with or
without consideration, this Warrant or any of the Warrant Shares (or a portion thereof) to the Holder’s Affiliates (as such
term is defined under Rule 144 of the Securities Act) without obtaining the opinion from counsel that may be required by Section
4(c)(ii), provided, that the Holder delivers to the Company and its counsel certification, documentation, and other assurances
reasonably required by the Company’s counsel to enable the Company’s counsel to render an opinion to the Company’s
Transfer Agent that such transfer does not violate applicable securities laws.

 

5.          MUTILATED
OR MISSING WARRANT CERTIFICATE

 

If this Warrant is
mutilated, lost, stolen or destroyed, upon request by the Holder, the Company will, at its expense, issue, in exchange for and
upon cancellation of the mutilated Warrant, or in substitution for the lost, stolen or destroyed Warrant, a new Warrant, in substantially
the form of this Warrant, representing the right to acquire the equivalent number of Warrant Shares; provided, that, as
a prerequisite to the issuance of a substitute Warrant, the Company may require satisfactory evidence of loss, theft or destruction
as well as an indemnity from the Holder of a lost, stolen or destroyed Warrant.

 

6.          PAYMENT
OF TAXES

 

The Company will pay
all transfer and stock issuance taxes attributable to the preparation, issuance and delivery of this Warrant and the Warrant Shares
(and replacement Warrants) including, without limitation, all documentary and stamp taxes; provided, however, that
the Company shall not be required to pay any tax in respect of the transfer of this Warrant, or the issuance or delivery of certificates
for Warrant Shares or other securities in respect of the Warrant Shares to any person or entity other than to the Holder.

 

7.          FRACTIONAL
WARRANT SHARES

 

No fractional Warrant
Shares shall be issued upon exercise of this Warrant. Upon the full exercise of this Warrant, the Company, in lieu of issuing any
fractional Warrant Share, shall round up the number of Warrant Shares issuable to nearest whole share.

 

 

 

    	8

    	 

    

 

 

8.          NO
STOCK RIGHTS AND LEGEND

 

No holder of this Warrant,
as such, shall be entitled to vote or be deemed the holder of any other securities of the Company that may at any time be issuable
on the exercise hereof, nor shall anything contained herein be construed to confer upon the holder of this Warrant, as such, the
rights of a stockholder of the Company or the right to vote for the election of directors or upon any matter submitted to stockholders
at any meeting thereof, or give or withhold consent to any corporate action or to receive notice of meetings or other actions affecting
stockholders (except as provided herein), or to receive dividends or subscription rights or otherwise (except as provide herein).

 

Each certificate for
Warrant Shares initially issued upon the exercise of this Warrant, and each certificate for Warrant Shares issued to any subsequent
transferee of any such certificate, shall be stamped or otherwise imprinted with a legend in substantially the following form:

 

THE SECURITIES REPRESENTED
HEREBY HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”)
OR ANY STATE SECURITIES LAWS. THESE SECURITIES MAY BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED ONLY (A) TO THE COMPANY,
(B) IN COMPLIANCE WITH RULE 144 UNDER THE SECURITIES ACT, IF AVAILABLE, AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS,
(C) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT, OR (D) IN A TRANSACTION THAT DOES NOT REQUIRE REGISTRATION UNDER THE SECURITIES
ACT OR ANY APPLICABLE STATE SECURITIES LAWS, AND THE HOLDER HAS, PRIOR TO SUCH SALE, FURNISHED TO THE COMPANY AN OPINION OF COUNSEL
OR OTHER EVIDENCE OF EXEMPTION, IN EITHER CASE REASONABLY SATISFACTORY TO THE COMPANY. HEDGING TRANSACTIONS INVOLVING THESE SECURITIES
MAY NOT BE CONDUCTED UNLESS IN COMPLIANCE WITH THE SECURITIES ACT.

 

9.          REGISTRATION
RIGHTS

 

The Holder shall be
entitled to the registration rights with respect to the Warrant Shares set forth in, and subject to the conditions of, the Registration
Rights Agreement.

 

10.         NOTICES

 

All notices, consents,
waivers, and other communications under this Warrant must be in writing and will be deemed given to a party when (a) delivered
to the appropriate address by hand or by nationally recognized overnight courier service (costs prepaid); (b) sent by facsimile
or e-mail with confirmation of transmission by the transmitting equipment; (c) received or rejected by the addressee, if sent by
certified mail, return receipt requested, if to the registered Holder hereof; or (d) seven days after the placement of the notice
into the mails (first class postage prepaid), to the Holder at the address, facsimile number, or e-mail address furnished by the
registered Holder to the Company in accordance with the Subscription Agreement by and between the Company and the Holder or, if
the registered Holder is not the original purchaser of this Warrant, then as provided in the Form of Assignment delivered to the
Company pursuant to Section 4(a) in connection with the assignment of this Warrant to such Holder, or if to the Company, to it
at:

 

    	9

    	 

    

 

Ekso Bionics Holdings, Inc.

1414 Harbour Way South, Suite 1201

Richmond, CA 94804

Attn: Chief Financial Officer

Facsimile Number: (510) 927-2647

Telephone Number: (203) 723-3576

E-mail Address: investors@eksobionics.com

 

(or to such other address, facsimile number,
or e-mail address as the Holder or the Company as a party may designate by notice to the other party in accordance with this Section
10) with a copy to

 

Attn:

Facsimile Number:

Telephone Number:

E-mail Address:

 

11.         SEVERABILITY

 

If a court of competent
jurisdiction holds any provision of this Warrant invalid or unenforceable, the other provisions of this Warrant will remain in
full force and effect. Any provision of this Warrant held invalid or unenforceable only in part or degree will remain in full force
and effect to the extent not held invalid or unenforceable.

 

12.         BINDING
EFFECT

 

This Warrant shall
be binding upon and inure to the sole and exclusive benefit of the Company, its successors and assigns, the registered Holder or
Holders from time to time of this Warrant and the Warrant Shares.

 

13.         SURVIVAL
OF RIGHTS AND DUTIES

 

This Warrant shall
terminate and be of no further force and effect on the earlier of 5:00 P.M., Eastern Time, on the Expiration Date or the date on
which this Warrant has been exercised in full.

 

14.         GOVERNING
LAW

 

This Warrant will be
governed by and construed under the laws of the State of New York without regard to conflicts of laws principles that would require
the application of any other law.

 

    	10

    	 

    

 

15.         DISPUTE
RESOLUTION

 

In the case of a dispute
as to the determination of the Exercise Price or the arithmetic calculation of the Warrant Shares, the Company shall submit the
disputed determinations or arithmetic calculations via facsimile within five (5) Business Days of receipt of the Notice of Exercise
giving rise to such dispute, as the case may be, to the Holder. If the Holder and the Company are unable to agree upon such determination
or calculation of the Exercise Price or the Warrant Shares within three Business Days of such disputed determination or arithmetic
calculation being submitted to the Holder, then the Company shall, at its sole discretion, within five (5) Business Days, submit
via facsimile (a) the disputed determination of the Exercise Price to an independent, reputable investment bank selected by the
Company and approved by the Holder, or (b) the disputed arithmetic calculation of the Warrant Shares to the Company’s independent,
outside accountant. The Company shall cause at its expense the investment bank or the accountant, as the case may be, to perform
the determinations or calculations and notify the Company and the Holder of the results no later than ten (10) Business Days from
the time it receives the disputed determinations or calculations; provided that, if such disputed determination or arithmetic calculation
being submitted by the Holder is determined to be incorrect, then the expense of the investment bank or the accountant shall be
the responsibility of the Holder. Such investment bank’s or accountant’s determination or calculation, as the case
may be, shall be final, binding and conclusive upon the parties thereto.

 

16.         NOTICES
OF RECORD DATE

 

Upon (a) any establishment
by the Company of a record date of the holders of any class of securities for the purpose of determining the holders thereof who
are entitled to receive any dividend or other distribution, or right or option to acquire securities of the Company, or any other
right, or (b) any capital reorganization, reclassification, recapitalization, merger or consolidation of the Company with or into
any other corporation, any transfer of all or substantially all the assets of the Company, or any voluntary or involuntary dissolution,
liquidation or winding up of the Company, or the sale, in a single transaction, of a majority of the Company’s voting stock
(whether newly issued, or from treasury, or previously issued and then outstanding, or any combination thereof), the Company shall
mail to the Holder at least ten (10) Business Days, or such longer period as may be required by law, prior to the record date specified
therein, a notice specifying (i) the date established as the record date for the purpose of such dividend, distribution, option
or right and a description of such dividend, option or right, (ii) the date on which any such reorganization, reclassification,
transfer, consolidation, merger, dissolution, liquidation or winding up, or sale is expected to become effective and (iii) the
date, if any, fixed as to when the holders of record of Common Stock shall be entitled to exchange their shares of Common Stock
for securities or other property deliverable upon such reorganization, reclassification, transfer, consolation, merger, dissolution,
liquidation or winding up.

 

    	11

    	 

    

 

17.         RESERVATION
OF SHARES

 

The Company shall reserve
and keep available out of its authorized but unissued shares of Common Stock for issuance upon the exercise of this Warrant, free
from pre-emptive rights, such number of shares of Common Stock for which this Warrant shall from time to time be exercisable. The
Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein
without violation of any applicable law or regulation. Without limiting the generality of the foregoing, the Company covenants
that it will use commercially reasonable efforts to take all such action as may be necessary or appropriate in order that the Company
may validly and legally issue fully paid and non-assessable Warrant Shares upon the exercise of this Warrant and use commercially
reasonable efforts to obtain all such authorizations, exemptions or consents, including but not limited to consents from the Company’s
stockholders or Board of Directors or any public regulatory body, as may be necessary to enable the Company to perform its obligations
under this Warrant.

 

18.         HEADINGS

 

The headings used in
this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.

 

19.         AMENDMENT
AND WAIVERS

 

Any term of this Warrant
may be amended and the observance of any term of this Agreement may be waived (either generally or in a particular instance and
either retroactively or prospectively), with the written consent of the Company and the Holders of a majority of the Warrant Shares
issuable upon exercise of the Warrants.

 

20.         NO
THIRD PARTY RIGHTS

 

This Warrant is not
intended, and will not be construed, to create any rights in any parties other than the Company and the Holder, and no person or
entity may assert any rights as third-party beneficiary hereunder.

 

[SIGNATURE PAGE FOLLOWS]

 

 

    	12

    	 

    

 

IN WITNESS WHEREOF,
the Company has caused this Warrant to be duly executed as of the date first set forth above.

 

	 	EKSO BIONICS HOLDINGS, INC.	 
	 	 	 	 
	 	By: 	 	 
	 	 	Name:	 
	 	 	Title:	 

  

    	 

    	 

    

EXHIBIT A

 

NOTICE OF EXERCISE

 

(To be executed by the Holder of Warrant
if such Holder desires to exercise Warrant)

 

To EKSO BIONICS HOLDINGS, INC.:

 

The undersigned hereby
irrevocably elects to exercise this Warrant and to purchase thereunder, ___________________ full shares of Ekso Bionics Holdings,
Inc. common stock issuable upon exercise of the Warrant and delivery of $_________ (in cash as provided for in the foregoing Warrant)
and any applicable taxes payable by the undersigned pursuant to such Warrant.

 

The undersigned
requests that certificates for such shares be issued in the name of:

 

_________________________________________

 

_________________________________________

 

_________________________________________

 

(Please print name, address and social security
or federal employer

identification number (if applicable))*

 

If the shares issuable
upon this exercise of the Warrant are not all of the Warrant Shares which the Holder is entitled to acquire upon the exercise of
the Warrant, the undersigned requests that a new Warrant evidencing the rights not so exercised be issued in the name of and delivered
to:

 

_________________________________________

 

_________________________________________

 

_________________________________________

 

(Please print name, address and social security
or federal employer

identification number (if applicable))*

  

	 	Name of Holder (print):	 

	 	(Signature):	 
	 	(By:)  	 
	 	(Title:) 	 
	 	Dated:	 

 

 

 

*        If Warrant Shares are to be issued
in any name other than that of the registered Holder of the Warrant, then the Holder must include an opinion of counsel, reasonably
satisfactory to the Company, to the effect that such issuance complies with all applicable securities laws.         

 

    	 

    	 

    

  

EXHIBIT B

 

FORM OF ASSIGNMENT

 

FOR VALUE RECEIVED,
___________________________________ hereby sells, assigns and transfers to each assignee set forth below all of the rights of the
undersigned under the Warrant (as defined in and evidenced by the attached Warrant) to acquire the number of Warrant Shares set
opposite the name of such assignee below and in and to the foregoing Warrant with respect to said acquisition rights and the shares
issuable upon exercise of the Warrant:

 

	
        Name of Assignee

(and social security or federal employer

identification number (if applicable))
	 	Address	 	Number of Shares
	
        

         
	 	 	 	 
	
          
	 	 	 	 
	
        

         
	 	 	 	 

 

If the total of the
Warrant Shares are not all of the Warrant Shares evidenced by the foregoing Warrant, the undersigned requests that a new Warrant
evidencing the right to acquire the Warrant Shares not so assigned be issued in the name of and delivered to the undersigned.

  

	 	Name of Holder (print):	 

	 	(Signature):	 
	 	(By:)  	 
	 	(Title:) 	 
	 	Dated:Exhibit 10.10

 

FORM OF

Registration
Rights Agreement

 

This Registration Rights
Agreement (this “Agreement”) is made and entered into effective as of _______________ ___, 2014, between
Ekso Bionics Holdings, Inc., a Nevada corporation (the “Company”), the persons who have executed omnibus
or counterpart signature page(s) hereto (each, a “Purchaser” and collectively, the “Purchasers,”
which terms, for avoidance of doubt, include all persons who purchased Bridge Notes (as defined below) and/or Units (as defined
below)), and the persons or entities identified on Schedule 1 hereto holding Bridge Placement Agent Warrants, Placement Agent Warrants
(each as defined below) or Lender Warrants (collectively, the “Other Holders”).

 

RECITALS:

 

WHEREAS, Ekso
Bionics, Inc., a Delaware corporation (the “Ekso”), has offered and sold in compliance with Rule 506 of Regulation
D promulgated under the Securities Act of 1933, as amended (the “Securities Act”), to accredited investors in
a private placement offering (the “Note Offering”), Ekso’s 10% Secured Convertible Promissory Notes with
a term of eight (8) months (the “Bridge Notes”), pursuant to that certain Securities Purchase Agreement
entered into by and between Ekso and buyer(s) of the Bridge Notes set forth on the signature pages affixed thereto (the “Bridge
Purchase Agreement”); and

 

WHEREAS, the
Company has offered and sold in compliance with Rule 506 of Regulation D promulgated under the Securities Act to accredited investors
in a private placement offering (the “PIPE”) its “Units,” each consisting of (i) one share
of the common stock of the Company, par value $0.001 per share (the “Common Stock”) and (ii) a warrant representing
the right to purchase one share of Common Stock, exercisable from issuance until five (5) years after the initial closing of the
PIPE at an exercise price of $2.00 per share (the “PIPE Warrants”), pursuant to that certain Subscription Agreement
entered into by and between the Company and subscribers for the Units set forth on the signature pages affixed thereto (the “PIPE
Subscription Agreement”); and

 

WHEREAS, in
connection with the consummation of the PIPE and the merger of the Company’s wholly-owned subsidiary with and into Ekso (the
“Merger”), all of the Bridge Notes have been converted into Units and warrants to purchase a number of shares of Common
Stock equal to the number of shares of Common Stock contained in the Units into which the Bridge Notes converted, exercisable for
a term of three (3) years at an exercise price per share of $1.00 (the “Bridge Warrants”) at the Conversion
Price (as defined in the Bridge Notes); and

 

WHEREAS, the
Company has agreed to enter into a registration rights agreement with each of the Purchasers in the PIPE who purchased the Units;
and

 

WHEREAS, in
connection with the Note Offering, Ekso agreed to cause the Company to enter into a registration rights agreement with each of
the Purchasers who purchased Bridge Notes granting such Purchasers registration rights with respect to the shares of Common Stock
issued to such Purchasers upon the converstion of the Bridge Notes into Units, shares of Common Stock issuable upon exercise of
the PIPE Warrants issued to such Purchaser upon the conversion of the Bridge Notes into Units, and upon exercise of the Bridge
Warrants issued to such Purchaser, in each case on a pari passu basis with, and upon substantially the same terms as the registration
rights granted to, the Purchasers of Units in the PIPE; and

 

    	 

    	 

    

 

WHEREAS, the
Company has agreed with the Placement Agent (as defined in the PIPE Subscription Agreement) that the shares of Common Stock issuable
upon exercise of the Bridge Placement Agent Warrants and the Placement Agent Warrants shall be included in the Registration Statement
and has agreed with that the Lender Warrants shall contain substantially the same terms as the Bridge Placement Agent Warrants.

 

Now,
Therefore, in consideration of the mutual promises, representations, warranties, covenants, and conditions set forth
herein, the parties mutually agree as follows:

 

1.          Certain
Definitions. As used in this Agreement, the following terms shall have the following respective meanings:

 

“Approved
Market” means the OTC Markets Group, the Nasdaq Stock Market, the New York Stock Exchange or the NYSE Amex.

 

“Blackout
Period” means, with respect to a registration, a period during which the Company, in the good faith judgment of its board
of directors, determines (because of the existence of, or in anticipation of, any acquisition, financing activity, or other transaction
involving the Company, or the unavailability for reasons beyond the Company’s control of any required financial statements,
disclosure of information which is in its best interest not to publicly disclose, or any other event or condition of similar significance
to the Company) that the registration and distribution of the Registrable Securities to be covered by such registration statement,
if any, would be seriously detrimental to the Company and its stockholders, in each case commencing on the day immediately after
the Company notifies the Holders that they are required, because of the determination described above, to suspend offers and sales
of Registrable Securities and ending on the earlier of (1) the date upon which the material non-public information resulting in
the Blackout Period is disclosed to the public or ceases to be material and (2) such time as the Company notifies the selling Holders
that sales pursuant to such Registration Statement or a new or amended Registration Statement may resume.

 

“Bridge Placement
Agent Warrants” shall have the meaning set forth in the Subscription Agreement.

 

“Business
Day” means any day of the year, other than a Saturday, Sunday, or other day on which banks in the State of New York are
required or authorized to close.

 

“Commission”
means the U. S. Securities and Exchange Commission or any other federal agency at the time administering the Securities Act.

 

    	2

    	 

    

 

“Common Stock”
means the common stock, par value $0.001 per share, of the Company and any and all shares of capital stock or other equity securities
of: (i) the Company which are added to or exchanged or substituted for the Common Stock by reason of the declaration of any stock
dividend or stock split, the issuance of any distribution or the reclassification, readjustment, recapitalization or other such
modification of the capital structure of the Company; and (ii) any other corporation, now or hereafter organized under the laws
of any state or other governmental authority, with which the Company is merged, which results from any consolidation or reorganization
to which the Company is a party, or to which is sold all or substantially all of the shares or assets of the Company, if immediately
after such merger, consolidation, reorganization or sale, the Company or the stockholders of the Company own equity securities
having in the aggregate more than 50% of the total voting power of such other corporation.

 

“Effective
Date” means the date of the final closing of the PIPE.

 

“Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations of the Commission promulgated
thereunder.

 

“Family Member”
means (a) with respect to any individual, such individual’s spouse, any descendants (whether natural or adopted), any trust
all of the beneficial interests of which are owned by any of such individuals or by any of such individuals together with any organization
described in Section 501(c)(3) of the Internal Revenue Code of 1986, as amended, the estate of any such individual, and any corporation,
association, partnership or limited liability company all of the equity interests of which are owned by those above described individuals,
trusts or organizations and (b) with respect to any trust, the owners of the beneficial interests of such trust.

 

“Holder”
means (i) each Purchaser or any of such Purchaser’s respective successors and Permitted Assignees who acquire rights in accordance
with this Agreement with respect to any Registrable Securities directly or indirectly from a Purchaser or from any Permitted Assignee
and (ii) each Other Holder or any of such Other Holder’s respective successors and Permitted Assignees who acquire rights
in accordance with this Agreement with respect to any Registrable Securities directly or indirectly from an Other Holder or from
any Permitted Assignee.

 

“Lender Warrants”
means the warrant to purchase up to 225,000 shares of Common Stock issued to a certain lender of Ekso pursuant to a certain letter
agreement between the lender and Ekso dated November 15, 2013.

 

“Majority
Holders” means, at any time, Holders of a majority of the Registrable Securities then outstanding.

 

“Permitted
Assignee” means (a) with respect to a partnership, its partners or former partners in accordance with their partnership
interests, (b) with respect to a corporation, its stockholders in accordance with their interest in the corporation, (c) with respect
to a limited liability company, its members or former members in accordance with their interest in the limited liability company,
(d) with respect to an individual party, any Family Member of such party, (e) an entity that is controlled by, controls, or is
under common control with a transferor, or (f) a party to this Agreement.

 

“Piggyback
Registration” means, in any registration of Common Stock referenced in Section 3(b), the right of each Holder to include
the Registrable Securities of such Holder in such registration.

 

    	3

    	 

    

 

“Placement
Agent Warrants” shall have the meaning set forth in the Subscription Agreement.

 

The terms “register,”
“registered,” and “registration” refer to a registration effected by preparing and filing
a registration statement in compliance with the Securities Act, and the declaration or ordering of the effectiveness of such registration
statement.

 

“Registrable
Securities” means (a) the Shares, (b) the shares of Common Stock issuable upon exercise of the Bridge Warrants, (c) the
shares of Common Stock issuable upon exercise of the PIPE Warrants, (d) the shares of Common Stock issuable upon exercise of the
Bridge Placement Agent Warrants, (e) the shares of Common Stock issuable upon exercise of the Placement Agent Warrants, and (f)
the shares of Common Stock issuable upon the exercise of the Lender Warrants; but, in each case, excluding any otherwise Registrable
Securities that (i) have been sold or otherwise transferred other than to a Permitted Assignee, (ii) may be sold under the Securities
Act without volume limitations either pursuant to Rule 144 of the Securities Act or otherwise during any ninety (90) day period,
or (iii) are at the time subject to an effective registration statement under the Securities Act.

 

“Registration
Default Period” means the period during which any Registration Event occurs and is continuing.

 

“Registration
Effectiveness Date” means the date that is one hundred and eighty (180) calendar days after the Registration Statement
is first filed with the Commission.

 

“Registration
Event” means the occurrence of any of the following events:

 

(a)          the
Company fails to file with the Commission the Registration Statement on or before the Registration Filing Date;

 

(b)          the
Registration Statement is not declared effective by the Commission on or before the Registration Effectiveness Date;

 

(c)          after
the SEC Effective Date, the Registration Statement ceases for any reason to remain continuously effective or the Holders are otherwise
not permitted to utilize the prospectus therein to resell the Registrable Securities, for more than thirty (30) consecutive calendar
days, except as excused pursuant to Section 3(a) and except during any Blackout Period; or

 

(d)          the
Registrable Securities, if issued, are not listed or included for quotation on an Approved Market, or trading of the Common Stock
is suspended or halted on the Approved Market, which at the time constitutes the principal market for the Common Stock, for more
than three (3) full, consecutive Trading Days; provided, however, a Registration Event shall not be deemed to occur
if all or substantially all trading in equity securities (including the Common Stock) of the Company is suspended or halted on
the Approved Market for any length of time.

 

“Registration
Filing Date” means the later to occur of (i) the date that is ninety (90) calendar days after the Effective Date and
(ii) the date that is two (2) Business Days following the filing due date for the Company’s Annual Report on Form 10-K for
the fiscal year ended December 31, 2013 (i.e., April 2, 2014).

 

    	4

    	 

    

 

“Registration
Statement” means the registration statement that the Company is required to file pursuant to Section 3(a) of this Agreement
to register the Registrable Securities.

 

“Rule 144”
means Rule 144 promulgated by the Commission under the Securities Act, as such rule may be amended or supplemented from time to
time, or any similar successor rule that may be promulgated by the Commission.

 

“Rule 145”
means Rule 145 promulgated by the Commission under the Securities Act, as such rule may be amended or supplemented from time to
time, or any similar successor rule that may be promulgated by the Commission.

 

“Rule 415”
means Rule 415 promulgated by the Commission under the Securities Act, as such rule may be amended or supplemented from time to
time, or any similar successor rule that may be promulgated by the Commission.

 

“Securities
Act” means the Securities Act of 1933, as amended, or any similar federal statute promulgated in replacement thereof,
and the rules and regulations of the Commission thereunder, all as the same shall be in effect at the time.

 

“SEC Effective
Date” means the date the Registration Statement is declared effective by the Commission.

 

“Shares”
means the shares of Common Stock issued to the Purchasers pursuant to the PIPE Subscription Agreement, the shares of Common Stock
issued to the Purchasers upon conversion of the Bridge Notes into Units, and any shares of Common Stock issued or issuable with
respect to such shares upon any stock split, dividend or other distribution, recapitalization or similar event with respect to
the foregoing.

 

“Trading Day”
means any day on which such national securities exchange, the OTC Markets Group or such other securities market or quotation system,
which at the time constitutes the principal securities market for the Common Stock, is open for general trading of securities.

 

Capitalized terms used
herein without definition have the meanings ascribed to them in the Bridge Purchase Agreement or the PIPE Subscription Agreement,
as the case may be.

 

2.          Term.
This Agreement shall terminate with respect to each Holder on the earlier of: (i) the date that is the later of (x) one year from
the SEC Effective Date and (y) the date on which all Registrable Securities held by such Holder are transferred other than to a
Permitted Transferee or may be sold under Rule 144 without volume limitations during any ninety (90) day period; or (ii) the
date otherwise terminated as provided herein.

 

    	5

    	 

    

 

3.           Registration.

 

(a)          Registration
on Form S-1. The Company shall file with the Commission a Registration Statement on Form S-1, or any other form for which the
Company then qualifies or which counsel for the Company shall deem appropriate and which form shall be available for the resale
by the Holders of all of the Registrable Securities, and the Company shall (i) use its commercially reasonable efforts to make
the initial filing of the Registration Statement no later than the Registration Filing Date, (ii) use its commercially reasonable
efforts to cause such Registration Statement to be declared effective no later than the Registration Effectiveness Date and (iii)
use its commercially reasonable efforts to keep such Registration Statement effective for a period of one (1) year or for such
shorter period ending on the earlier to occur of (i) the sale of all Registrable Securities and (ii) the availability of Rule 144
for the Holder to sell all of the Registrable Securities without volume limitations within a 90 day period (the “Effectiveness
Period”); provided, however, that the Company shall not be obligated to effect any such registration, qualification
or compliance pursuant to this Section, or keep such registration effective pursuant to the terms hereunder, in any particular
jurisdiction in which the Company would be required to qualify to do business as a foreign corporation or as a dealer in securities
under the securities laws of such jurisdiction or to execute a general consent to service of process in effecting such registration,
qualification or compliance, in each case where it has not already done so. Notwithstanding the foregoing, in the event that the
Commission should limit the number of Registrable Securities that may be sold pursuant to the Registration Statement, the Company
may remove from the Registration Statement such number of Registrable Securities as specified by the Commission (the “Cut
Back Shares”) on behalf of all of the holders of Registrable Securities on the following basis: first any Bridge Brokers’
Shares and PIPE Broker’s Shares shall be excluded from the Registration Statement on a pro rata basis, and then if additional
Registrable Securities must be excluded, on behalf of all other holders of Registrable Securities on a pro rata basis. In such
event, the Company shall give the Holders prompt notice of the number of Registrable Securities excluded therefrom. No partial
liquidated damages (such as set forth in Section 3(d)) shall accrue to any Cut Back Shares.

 

(b)          Piggyback
Registration. Piggyback Registration rights shall apply to any Registrable Securities that are removed from the Registration
Statement as a result of a requirement by the Commission. If, after the SEC Effective Date, the Company shall determine to register
for sale for cash any of its Common Stock, for its own account or for the account of others (other than the Holders), other than
(x) a registration relating solely to employee benefit plans or securities issued or issuable to employees, consultants (to the
extent the securities owned or to be owned by such consultants could be registered on Form S-8) or any of their Family Members
(including a registration on Form S-8), (y) a registration relating solely to a Securities Act Rule 145 transaction or a registration
on Form S-4 in connection with a merger, acquisition, divestiture, reorganization or similar event, or (z) a transaction relating
solely to the sale of debt or convertible debt instruments, then the Company shall promptly give to each Holder written notice
thereof (the “Registration Rights Notice”) (and in no event shall such notice be given less than twenty (20)
calendar days prior to the filing of such registration statement), and shall, subject to Section 3(c), include as a Piggyback Registration
all of the Registrable Securities specified in a written request delivered by the Holder thereof within ten (10) calendar days
after delivery to the Holder of such written notice from the Company. However, the Company may, without the consent of such Holders,
withdraw such registration statement prior to its becoming effective if the Company or such other selling stockholders have elected
to abandon the proposal to register the securities proposed to be registered thereby.

 

    	6

    	 

    

 

(c)          Underwriting.
If a Piggyback Registration is for a registered public offering that is to be made by an underwriting, the Company shall so advise
the Holders as part of the Registration Rights Notice. In that event, the right of any Holder to Piggyback Registration shall be
conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities
in the underwriting to the extent provided herein. All Holders proposing to sell any of their Registrable Securities through such
underwriting shall (together with the Company and any other stockholders of the Company selling their securities through such underwriting)
enter into an underwriting agreement in customary form with the underwriter selected for such underwriting by the Company or such
other selling stockholders, as applicable. Notwithstanding any other provision of this Section 3(c), if the underwriter or the
Company determines that marketing factors require a limitation on the number of shares of Common Stock or the amount of other securities
to be underwritten, the underwriter may exclude some or all Registrable Securities from such registration and underwriting. The
Company shall so advise all Holders (except those Holders who failed to timely elect to include their Registrable Securities through
such underwriting or have indicated to the Company their decision not to do so), and indicate to each such Holder the number of
shares of Registrable Securities that may be included in the registration and underwriting, if any. The number of shares of Registrable
Securities to be included in such registration and underwriting shall be allocated among such Holders as follows:

 

(i)          If
the Piggyback Registration was initiated by the Company, the number of shares that may be included in the registration and underwriting
shall be allocated first to the Company and then, subject to obligations and commitments existing as of the date hereof, to all
persons exercising piggyback registration rights (including the Holders) who have requested to sell in the registration on a pro
rata basis according to the number of shares requested to be included therein; and

 

(ii)         If
the Piggyback Registration was initiated by the exercise of demand registration rights by a stockholder or stockholders of the
Company, then the number of shares that may be included in the registration and underwriting shall be allocated first to such selling
stockholders who exercised such demand to the extent of their demand registration rights, and then, subject to obligations and
commitments existing as of the date hereof, to the Company and then, subject to obligations and commitments existing as of the
date hereof, to all persons exercising piggyback registration rights (including the Holders) who have requested to sell in the
registration on a pro rata basis according to the number of shares requested to be included therein.

 

No Registrable Securities
excluded from the underwriting by reason of the underwriter’s marketing limitation shall be included in such registration.
If any Holder disapproves of the terms of any such underwriting, such Holder may elect to withdraw such Holder’s Registrable
Securities therefrom by delivering a written notice to the Company and the underwriter. The Registrable Securities so withdrawn
from such underwriting shall also be withdrawn from such registration; provided, however, that, if by the withdrawal
of such Registrable Securities, a greater number of Registrable Securities held by other Holders may be included in such registration
(up to the maximum of any limitation imposed by the underwriters), then the Company shall offer to all Holders who have included
Registrable Securities in the registration the right to include additional Registrable Securities pursuant to the terms and limitations
set forth herein in the same proportion used above in determining the underwriter limitation.

 

    	7

    	 

    

 

(d)          Liquidated
Damages. If a Registration Event occurs, then the Company will make payments to each Holder of Registrable Securities, as partial
liquidated damages to such Holder by reason of the Registration Event, a cash sum equal to one percent (1%) of the aggregate purchase
price paid by such Holder pursuant to the Bridge Purchase Agreement or PIPE Subscription Agreement, as applicable, with respect
to such Holder’s Registrable Securities which are affected by such Registration Event, for each full thirty (30) days during
which such Registration Event continues to affect such Registrable Securities (which shall be pro-rated for any period less than
30 days). For the sake of clarity, the partial liquidated damages contemplated by this Section 3(d) shall not be payable in respect
of any of the Registrable Securities identified in clauses (d), (e) and (f) of the definition of Registrable Securities. Notwithstanding
the foregoing, the maximum amount of liquidated damages that may be paid by the Company pursuant to this Section 3(d) shall be
an amount equal to eight percent (8%) of the aggregate purchase price paid by all Holders pursuant to the Bridge Purchase Agreement
or PIPE Subscription Agreement with respect to the Registrable Securities that are affected by all Registration Events in the aggregate.
Each payment of liquidated damages pursuant to this Section 3(d) shall be due and payable in arrears within five (5) days after
the end of each full 30-day period of the Registration Default Period until the termination of the Registration Default Period
and within five (5) days after such termination. Such payments shall constitute the Holder’s exclusive remedy for any Registration
Event. The Registration Default Period shall terminate upon the earlier of such time as the Registrable Securities that are affected
by the Registration Event cease to be Registable Securities or (i) the filing of the Registration Statement in the case of clause
(a) of the definition of Registration Event, (ii) the SEC Effective Date in the case of clause (b) of the definition of Registration
Event, (iii) the ability of the Holders to effect sales pursuant to the Registration Statement in the case of clause (c) of the
definition of Registration Event, and (iv) the listing or inclusion and/or trading of the Common Stock on an Approved Market, as
the case may be, in the case of clause (d) of the definition of Registration Event. The amounts payable as liquidated damages pursuant
to this Section 3(d) shall be payable in lawful money of the United States. Notwithstanding the foregoing, the Company will not
be liable for the payment of liquidated damages described in this Section 3(d) for any delay in registration of Registrable Securities
that would otherwise be includable in the Registration Statement pursuant to Rule 415 solely as a result of a comment received
by the Commission requiring a limit on the number of Registrable Securities included in such Registration Statement in order for
such Registration Statement to be able to avail itself of Rule 415. In the event of any such delay, the Company will use its commercially
reasonable efforts at the first opportunity that is permitted by the Commission to register for resale the Registrable Securities
that have been cut back from being registered pursuant to Rule 415 only with respect to that portion of the Holders’ Registrable
Securities that are then Registrable Securities.

 

    	8

    	 

    

 

(e)          Notwithstanding
the provisions of Section 3(d) above, if (i) the Commission does not declare the Registration Statement effective on or before
the Registration Effectiveness Date, or (ii) the Commission allows the Registration Statement to be declared effective at any time
before or after the Registration Effectiveness Date, subject to the withdrawal of certain Registrable Securities from the Registration
Statement, and the reason for (i) or (ii) is the Commission’s determination that (x) the offering of any of the Registrable
Securities constitutes a primary offering of securities by the Company, (y) Rule 415 may not be relied upon for the registration
of the resale of any or all of the Registrable Securities, and/or (z) a Holder of any Registrable Securities must be named as an
underwriter, the Holders understand and agree that in the case of (ii) the Company may (notwithstanding anything to the contrary
contained herein) reduce, on a pro rata basis, the total number of Registrable Securities to be registered on behalf of each such
Holder, and in the case of (i) or (ii) the Holder shall not be entitled to partial liquidated damages with respect to the Registrable
Securities not registered for the reason set forth in (a) or so reduced on a pro rata basis as set forth in (i).

 

4.           Registration
Procedures. The Company will keep each Holder reasonably advised as to the filing and effectiveness of the Registration Statement.
At its expense with respect to the Registration Statement, the Company will:

 

(a)          prepare
and file with the Commission with respect to the Registrable Securities, a Registration Statement in accordance with Section 3(a)hereof,
and use its commercially reasonable efforts to cause such Registration Statement to become effective and to remain effective for
the Effectiveness Period;

 

(b)          if
the Registration Statement is subject to review by the Commission, promptly respond to all comments and diligently pursue resolution
of any comments to the satisfaction of the Commission;

 

(c)          prepare
and file with the Commission such amendments and supplements to such Registration Statement as may be necessary to keep such Registration
Statement effective during the Effectiveness Period;

 

(d)          furnish,
without charge, to each Holder of Registrable Securities covered by such Registration Statement (i) a reasonable number of copies
of such Registration Statement (including any exhibits thereto other than exhibits incorporated by reference), each amendment and
supplement thereto as such Holder may reasonably request, (ii) such number of copies of the prospectus included in such Registration
Statement (including each preliminary prospectus and any other prospectus filed under Rule 424 of the Securities Act) as such Holders
may reasonably request, in conformity with the requirements of the Securities Act, and (iii) such other documents as such Holder
may reasonably require to consummate the disposition of the Registrable Securities owned by such Holder, but only during the Effectiveness
Period;

 

(e)          use
its commercially reasonable efforts to register or qualify such registration under such other applicable securities laws of such
jurisdictions within the United States as any Holder of Registrable Securities covered by such Registration Statement reasonably
requests and as may be necessary for the marketability of the Registrable Securities (such request to be made by the time the applicable
Registration Statement is deemed effective by the Commission) and do any and all other acts and things necessary to enable such
Holder to consummate the disposition in such jurisdictions of the Registrable Securities owned by such Holder; provided,
that the Company shall not be required to (i) qualify generally to do business in any jurisdiction where it would not otherwise
be required to qualify but for this paragraph, (ii) subject itself to taxation in any such jurisdiction, or (iii) consent to general
service of process in any such jurisdiction.

 

    	9

    	 

    

 

(f)          as
promptly as practicable after becoming aware of such event, notify each Holder of Registrable Securities, the disposition of which
requires delivery of a prospectus relating thereto under the Securities Act, of the happening of any event, which comes to the
Company’s attention, that will after the occurrence of such event cause the prospectus included in such Registration Statement,
if not amended or supplemented, to contain an untrue statement of a material fact or an omission to state a material fact required
to be stated therein or necessary to make the statements therein not misleading and the Company shall promptly thereafter prepare
and furnish to such Holder a supplement or amendment to such prospectus (or prepare and file appropriate reports under the Exchange
Act) so that, as thereafter delivered to the purchasers of such Registrable Securities, such prospectus shall not contain an untrue
statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements
therein not misleading, unless suspension of the use of such prospectus otherwise is authorized herein or in the event of a Blackout
Period, in which case no supplement or amendment need be furnished (or Exchange Act filing made) until the termination of such
suspension or Blackout Period;

 

(g)          comply,
and continue to comply during the Effectiveness Period, in all material respects with the Securities Act and the Exchange Act and
with all applicable rules and regulations of the Commission with respect to the disposition of all securities covered by such Registration
Statement;

 

(h)          as
promptly as practicable after becoming aware of such event, notify each Holder of Registrable Securities being offered or sold
pursuant to the Registration Statement of the issuance by the Commission of any stop order or other suspension of effectiveness
of the Registration Statement;

 

(i)          use
its commercially reasonable efforts to cause all the Registrable Securities covered by the Registration Statement to be quoted
on the OTC Markets Group or such other principal securities market on which securities of the same class or series issued by the
Company are then listed or traded;

 

(j)          provide
a transfer agent and registrar, which may be a single entity, for the shares of Common Stock at all times;

 

(k)          cooperate
with the Holders of Registrable Securities being offered pursuant to the Registration Statement to issue and deliver, or cause
its transfer agent to issue and deliver, certificates representing Registrable Securities to be offered pursuant to the Registration
Statement within a reasonable time after the delivery of certificates representing the Registrable Securities to the transfer agent
or the Company, as applicable, and enable such certificates to be in such denominations or amounts as the Holders may reasonably
request and registered in such names as the Holders may request;

 

(l)          during
the Effectiveness Period, refrain from bidding for or purchasing any Common Stock or any right to purchase Common Stock or attempting
to induce any person to purchase any such security or right if such bid, purchase or attempt would in any way limit the right of
the Holders to sell Registrable Securities by reason of the limitations set forth in Regulation M of the Exchange Act; and

 

    	10

    	 

    

 

(m)          take
all other reasonable actions necessary to expedite and facilitate the disposition by the Holders of the Registrable Securities
pursuant to the Registration Statement during the term of this Agreement.

 

5.           Obligations
of the Holders.

 

(a)          Each
Holder agrees that, upon receipt of any notice from the Company of the happening of any event of the kind described in Section
4(f) hereof or of the commencement of a Blackout Period, such Holder shall discontinue the disposition of Registrable Securities
included in the Registration Statement until such Holder’s receipt of the copies of the supplemented or amended prospectus
contemplated by Section 4(f) hereof or notice of the end of the Blackout Period, and, if so directed by the Company, such Holder
shall deliver to the Company (at the Company’s expense) all copies (including, without limitation, any and all drafts), other
than permanent file copies, then in such Holder’s possession, of the prospectus covering such Registrable Securities current
at the time of receipt of such notice.

 

(b)          The
holders of the Registrable Securities shall provide such information as may reasonably be requested by the Company, or the managing
underwriter, if any, in connection with the preparation of any registration statement, including amendments and supplements thereto,
in order to effect the registration of any Registrable Securities under the Securities Act pursuant to Section 3(a) and/or 3(a)3(b)
of this Agreement and in connection with the Company’s obligation to comply with federal and applicable state securities
laws, including a completed questionnaire in the form attached to this Agreement as Annex A (a “Selling Securityholder
Questionnaire”) or any update thereto not later than three (3) Business Days following a request therefore from the Company.

 

(c)          Each
Holder, by its acceptance of the Registrable Securities, agrees to cooperate with the Company as reasonably requested by the Company
in connection with the preparation and filing of any Registration Statement hereunder, unless such Holder has notified the Company
in writing of its election to exclude all of its Registrable Securities from such Registration Statement.

 

6.           Registration
Expenses. The Company shall pay all expenses in connection with any registration obligation provided herein, including, without
limitation, all registration, filing, stock exchange fees, printing expenses, all fees and expenses of complying with applicable
securities laws, and the fees and disbursements of counsel for the Company and of its independent accountants; provided,
that, in any underwritten registration, the Company shall have no obligation to pay any underwriting discounts, selling commissions
or transfer taxes attributable to the Registrable Securities being sold by the Holders thereof, which underwriting discounts, selling
commissions and transfer taxes shall be borne by such Holders. Additionally, in an underwritten offering, all selling stockholders
and the Company shall bear the expenses of the underwriter pro rata in proportion to the respective amount of shares each is selling
in such offering. Except as provided in this Section 6 and Section 8 of this Agreement, the Company shall not be responsible for
the expenses of any attorney or other advisor employed by a Holder.

 

    	11

    	 

    

 

7.           Assignment
of Rights. No Holder may assign its rights under this Agreement to any party without the prior written consent of the Company;
provided, however, that any Holder may assign its rights under this Agreement without such consent to a Permitted
Assignee as long as (a) such transfer or assignment is effected in accordance with applicable securities laws; (b) such transferee
or assignee agrees in writing to become bound by and subject to the terms of this Agreement; and (c) such Holder notifies the Company
in writing of such transfer or assignment, stating the name and address of the transferee or assignee and identifying the Registrable
Securities with respect to which such rights are being transferred or assigned. the Company may assign this Agreement or any rights
or obligations hereunder without the prior written consent of the other party hereto.

 

8.           Indemnification.

 

(a)          In
the event of the offer and sale of Registrable Securities under the Securities Act, the Company shall, and hereby does, indemnify
and hold harmless, to the fullest extent permitted by law, each Holder, its directors, officers, partners, and each other person,
if any, who controls or is under common control with such Holder within the meaning of Section 15 of the Securities Act, against
any losses, claims, damages or liabilities, joint or several, and expenses to which the Holder or any such director, officer, partner
or controlling person may become subject under the Securities Act or otherwise, insofar as such losses, claims, damages, liabilities
or expenses (or actions or proceedings, whether commenced or threatened, in respect thereof) arise out of or are based upon any
untrue statement of any material fact contained in any registration statement prepared and filed by the Company under which Registrable
Securities were registered under the Securities Act, any preliminary prospectus, final prospectus or summary prospectus contained
therein, or any amendment or supplement thereto, or any omission to state therein a material fact required to be stated or necessary
to make the statements therein in light of the circumstances in which they were made not misleading, and the Company shall reimburse
the Holder, and each such director, officer, partner and controlling person for any legal or any other expenses reasonably incurred
by them in connection with investigating, defending or settling any such loss, claim, damage, liability, action or proceeding;
provided, however, that such indemnity agreement found in this Section 8(a) shall in no event exceed the net proceeds
from the Note Offering and the PIPE received by Ekso and the Company, respectively; and provided further, that the Company
shall not be liable in any such case (i) to the extent that any such loss, claim, damage, liability (or action or proceeding in
respect thereof) or expense arises out of or is based upon (a) an untrue statement in or omission from such registration statement,
any such preliminary prospectus, final prospectus, summary prospectus, amendment or supplement in reliance upon and in conformity
with written information furnished to the Company for use in the preparation thereof or (b) the failure of a Holder to comply with
the covenants and agreements contained in Section 5 hereof respecting the sale of Registrable Securities; or (ii) if the person
asserting any such loss, claim, damage, liability (or action or proceeding in respect thereof) who purchased the Registrable Securities
that are the subject thereof did not receive a copy of an amended preliminary prospectus or the final prospectus (or the final
prospectus as amended or supplemented) at or prior to the written confirmation of the sale of such Registrable Securities to such
person because of the failure of such Holder to so provide such amended preliminary or final prospectus and the untrue statement
or omission of a material fact made in such preliminary prospectus was corrected in the amended preliminary or final prospectus
(or the final prospectus as amended or supplemented). Such indemnity shall remain in full force and effect regardless of any investigation
made by or on behalf of the Holders, or any such director, officer, partner or controlling person and shall survive the transfer
of such shares by the Holder.

 

    	12

    	 

    

 

(b)          As
a condition to including Registrable Securities in any registration statement filed pursuant to this Agreement, each Holder agrees
to be bound by the terms of this Section 8 and to indemnify and hold harmless, to the fullest extent permitted by law, the Company,
each of its directors, officers, partners, legal counsel and accountants and each underwriter, if any, and each other person, if
any, who controls the Company within the meaning of Section 15 of the Securities Act, against any losses, claims, damages or liabilities,
joint or several, to which the Company or any such director or officer or controlling person may become subject under the Securities
Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions or proceedings, whether commenced or threatened,
in respect thereof) arise out of or are based upon any untrue statement of a material fact or any omission of a material fact required
to be stated in any registration statement, any preliminary prospectus, final prospectus, summary prospectus, amendment or supplement
thereto or necessary to make the statements therein not misleading, to the extent that such untrue statement or omission is included
or omitted in reliance upon and in conformity with written information furnished by the Holder for use in the preparation thereof,
and such Holder shall reimburse the Company, and such Holders, directors, officers, partners, legal counsel and accountants, persons,
underwriters, or control persons, each such director, officer, and controlling person for any legal or other expenses reasonably
incurred by them in connection with investigating, defending, or settling any such loss, claim, damage, liability, action, or proceeding;
provided, however, that indemnity obligation contained in this Section 8(b) shall in no event exceed the amount of
the net proceeds received by such Holder as a result of the sale of such Holder’s Registrable Securities pursuant to such
registration statement, except in the case of fraud or willful misconduct. Such indemnity shall remain in full force and effect,
regardless of any investigation made by or on behalf of the Company or any such director, officer or controlling person and shall
survive the transfer by any Holder of such shares.

 

(c)          Promptly
after receipt by an indemnified party of notice of the commencement of any action or proceeding involving a claim referred to in
this Section 8 (including any governmental action), such indemnified party shall, if a claim in respect thereof is to be made against
an indemnifying party, give written notice to the indemnifying party of the commencement of such action; provided, that
the failure of any indemnified party to give notice as provided herein shall not relieve the indemnifying party of its obligations
under this Section, except to the extent that the indemnifying party is actually prejudiced by such failure to give notice. In
case any such action is brought against an indemnified party, unless in the reasonable judgment of counsel to such indemnified
party a conflict of interest between such indemnified and indemnifying parties may exist or the indemnified party may have defenses
not available to the indemnifying party in respect of such claim, the indemnifying party shall be entitled to participate in and
to assume the defense thereof, with counsel reasonably satisfactory to such indemnified party and, after notice from the indemnifying
party to such indemnified party of its election so to assume the defense thereof, the indemnifying party shall not be liable to
such indemnified party for any legal or other expenses subsequently incurred by the latter in connection with the defense thereof,
unless in such indemnified party’s reasonable judgment a conflict of interest between such indemnified and indemnifying parties
arises in respect of such claim after the assumption of the defenses thereof or the indemnifying party fails to defend such claim
in a diligent manner, other than reasonable costs of investigation. Neither an indemnified nor an indemnifying party shall be liable
for any settlement of any action or proceeding effected without its consent. No indemnifying party shall, without the consent of
the indemnified party, consent to entry of any judgment or enter into any settlement, which does not include as an unconditional
term thereof the giving by the claimant or plaintiff to such indemnified party of a release from all liability in respect of such
claim or litigation. Notwithstanding anything to the contrary set forth herein, and without limiting any of the rights set forth
above, in any event any party shall have the right to retain, at its own expense, counsel with respect to the defense of a claim.
Each indemnified party shall furnish such information regarding itself or the claim in question as an indemnifying party may reasonably
request in writing and as shall be reasonably required in connection with defense of such claim and litigation resulting therefrom.

 

    	13

    	 

    

 

(d)          If
an indemnifying party does or is not permitted to assume the defense of an action pursuant to Sections 8(c) or in the case of the
expense reimbursement obligation set forth in Sections 8(a) and 8(b), the indemnification required by Sections 8(a) and 8(b) shall
be made by periodic payments of the amount thereof during the course of the investigation or defense, as and when bills are received
or expenses, losses, damages, or liabilities are incurred.

 

(e)          If
the indemnification provided for in Section 8(a) or 8(b) is held by a court of competent jurisdiction to be unavailable to an indemnified
party with respect to any loss, liability, claim, damage or expense referred to herein, the indemnifying party, in lieu of indemnifying
such indemnified party hereunder, shall contribute to the amount paid or payable by such indemnified party as a result of such
loss, liability, claim, damage or expense (i) in such proportion as is appropriate to reflect the proportionate relative fault
of the indemnifying party on the one hand and the indemnified party on the other (determined by reference to, among other things,
whether the untrue or alleged untrue statement of a material fact or omission relates to information supplied by the indemnifying
party or the indemnified party and the parties’ relative intent, knowledge, access to information and opportunity to correct
or prevent such untrue statement or omission), or (ii) if the allocation provided by clause (i) above is not permitted by applicable
law or provides a lesser sum to the indemnified party than the amount hereinafter calculated, then in such proportion as is appropriate
to reflect not only the proportionate relative fault of the indemnifying party and the indemnified party, but also the relative
benefits received by the indemnifying party on the one hand and the indemnified party on the other, as well as any other relevant
equitable considerations. No indemnified party guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the
Securities Act) shall be entitled to contribution from any indemnifying party who was not guilty of such fraudulent misrepresentation.

 

(f)          Notwithstanding
the foregoing, to the extent that the provisions on indemnification and contribution contained in the underwriting agreement entered
into in connection with an underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting
agreement shall control.

 

(g)          Other
Indemnification. Indemnification similar to that specified in this Section (with appropriate modifications) shall be given
by the Company and each Holder of Registrable Securities with respect to any required registration or other qualification of securities
under any federal or state law or regulation or governmental authority other than the Securities Act.

 

    	14

    	 

    

 

9.           Rule
144. The Company shall file with the Commission “Form 10 information” (as defined in Rule 144(i)(3) under the Securities
Act) reflecting its status as an entity that is no longer an issuer described in Rule 144(i)(1)(i) promptly following the closing
of the Merger. For a period extending from the date that is twelve (12) months after the filing of such Form 10 information until
at least twelve (12) months following the Effective Date, the Company shall (a) cause itself to be subject to the reporting requirements
of Section 13 or 15(d) of the Exchange Act and (b) use its commercially reasonable efforts to timely file all reports required
to be filed by the Company during such period under the Exchange Act and the rules and regulations adopted by the Commission thereunder.

 

10.         Independent
Nature of Each Purchaser’s Obligations and Rights. The obligations of each Purchaser and each Other Holder under this
Agreement are several and not joint with the obligations of any other Purchaser or Other Holder, and each Purchaser and each Other
Holder shall not be responsible in any way for the performance of the obligations of any other Purchaser or any Other Holder under
this Agreement. Nothing contained herein and no action taken by any Purchaser or Other Holder pursuant hereto, shall be deemed
to constitute such Purchasers and/or Other Holders as a partnership, an association, a joint venture, or any other kind of entity,
or create a presumption that the Purchasers and/or Other Holders are in any way acting in concert or as a group with respect to
such obligations or the transactions contemplated by this Agreement. Each Purchaser and each Other Holder shall be entitled to
independently protect and enforce its rights, including without limitation the rights arising out of this Agreement, and it shall
not be necessary for any other Purchaser or Other Holder to be joined as an additional party in any proceeding for such purpose.

 

11.         Miscellaneous.

 

(a)          Governing
Law. This Agreement shall be governed by and construed in accordance with the laws of the United States of America and the
State of New York, both substantive and remedial, without regard to New York conflicts of law principles. Any judicial proceeding
brought against either of the parties to this Agreement or any dispute arising out of this Agreement or any matter related hereto
shall be brought in the courts of the State of New York, New York County, or in the United States District Court for the Southern
District of New York and, by its execution and delivery of this Agreement, each party to this Agreement accepts the jurisdiction
of such courts. The foregoing consent to jurisdiction shall not be deemed to confer rights on any person other than the parties
to this Agreement.

 

(b)          Remedies.
In the event of a breach by the Company or by a Holder of any of their respective obligations under this Agreement, each Holder
or the Company, as the case may be, in addition to being entitled to exercise all rights granted by law and under this Agreement,
including recovery of damages, shall be entitled to specific performance of its rights under this Agreement. The Company and each
Holder agree that monetary damages would not provide adequate compensation for any losses incurred by reason of a breach by it
of any of the provisions of this Agreement and hereby further agrees that, in the event of any action for specific performance
in respect of such breach, it shall not assert or shall waive the defense that a remedy at law would be adequate.

 

    	15

    	 

    

 

(c)          Successors
and Assigns. Except as otherwise provided herein, the provisions hereof shall inure to the benefit of, and be binding upon,
the successors, Permitted Assignees, executors and administrators of the parties hereto.

 

(d)          No
Inconsistent Agreements. The Company has not entered, as of the date hereof, and shall not enter, on or after the date of this
Agreement, into any agreement with respect to its securities that would have the effect of impairing the rights granted to the
Holders in this Agreement or otherwise conflicts with the provisions hereof.

 

(e)          Entire
Agreement. This Agreement and the documents, instruments and other agreements specifically referred to herein or delivered
pursuant hereto constitute the full and entire understanding and agreement between the parties with regard to the subjects hereof.

 

(f)          Notices,
etc. All notices or other communications which are required or permitted under this Agreement shall be in writing and sufficient
if transmitted by hand delivery, by facsimile transmission, by registered or certified mail, postage pre-paid, by electronic mail,
or by nationally recognized overnight carrier, to the persons at the addresses set forth below (or at such other address as may
be provided hereunder), and shall be deemed to have been delivered (i) if transmitted by hand delivery, as of the date delivered,
(ii) if transmitted by facsimile or electronic mail, as of the date so transmitted with an automated confirmation of delivery,
(iii) if transmitted by nationally recognized overnight carrier, as of the Business Day following the date of delivery to the carrier,
and (iv) if transmitted by registered or certified mail, postage pre-paid, on the third Business Day following posting with the
U.S. Postal Service:

 

If to the Company, to:

 

Ekso Bionics Holdings, Inc.

1414 Harbour Way South, Suite 1201
Richmond, CA 94804

Attention:

Facsimile:

E-mail Address:

 

with copy to:

 

Attn:

Facsimile Number:

Telephone Number:

E-mail Address:

 

    	16

    	 

    

 

if to a Purchaser or Other Holder, to:

 

such Purchaser or Other Holder
at the address set forth on the signature page hereto;

 

or at such other address as any party shall have furnished to
the other parties in writing.

 

(g)          Delays
or Omissions. No delay or omission to exercise any right, power or remedy accruing to any Holder, upon any breach or default
of the Company under this Agreement, shall impair any such right, power or remedy of such Holder nor shall it be construed to be
a waiver of any such breach or default, or an acquiescence therein, or of any similar breach or default thereunder occurring; nor
shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring.
Any waiver, permit, consent or approval of any kind or character on the part of any Holder of any breach or default under this
Agreement, or any waiver on the part of any Holder of any provisions or conditions of this Agreement, must be in writing and shall
be effective only to the extent specifically set forth in such writing. All remedies, either under this Agreement, or by law or
otherwise afforded to any holder, shall be cumulative and not alternative.

 

(h)          Counterparts.
This Agreement may be executed in any number of counterparts, and with respect to any Purchaser, by execution of an Omnibus Signature
Page to this Agreement and the Bridge Purchase Agreement or PIPE Subscription Agreement, each of which shall be enforceable against
the parties actually executing such counterparts, and all of which together shall constitute one instrument. In the event that
any signature is delivered by facsimile transmission or by e-mail, such signature shall create a valid and binding obligation of
the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile signature
page were an original thereof.

 

(i)          Severability.
In the case any provision of this Agreement shall be invalid, illegal or unenforceable, the validity, legality and enforceability
of the remaining provisions shall not in any way be affected or impaired thereby.

 

(j)          Amendments.
Except as otherwise provided herein, the provisions of this Agreement may be amended at any time and from time to time, and particular
provisions of this Agreement may be waived, with and only with an agreement or consent in writing signed by the Company and the
Majority Holders. The Purchasers and Other Holders acknowledge that by the operation of this Section, the Majority Holders may
have the right and power to diminish or eliminate all rights of the Purchasers and/or Other Holders under this Agreement.

 

[COMPANY SIGNATURE
PAGE FOLLOWS]

 

    	17

    	 

    

 

This Registration Rights
Agreement is hereby executed as of the date first above written.

 

	 	The Company:
	 	 
	 	EKSO BIONICS HOLDINGS, INC.
	 	 	 
	 	By: 	 
	 	 	Name:  
	 	 	Title:  

 

	 	Purchasers
	 	 
	 	See Omnibus Signature Pages to Bridge Purchase Agreement and PIPE Subscription Agreement

 

	 	Other Holders:
	 	 	 
	 	 
	 	 	 
	 	By:	 
	 	 	Name:
	 	 	Title:
	 	 	 
	 	 
	 	 	 
	 	By:	 
	 	 	Name:
	 	 	Title:

 

    	18

    	 

    

 

Annex A

 

EKSO BIONICS HOLDINGS, INC.

 

Selling Securityholder Notice and Questionnaire

 

The undersigned beneficial
owner of Registrable Securities of Ekso Bionics Holdings, Inc., a Nevada corporation (the “Company”),
understands that the Company has filed or intends to file with the U.S. Securities and Exchange Commission a registration statement
(the “Registration Statement”) for the registration and resale under Rule 415 of the Securities Act of 1933,
as amended, of the Registrable Securities, in accordance with the terms of the Registration Rights Agreement (the “Registration
Rights Agreement”) to which this document is annexed. A copy of the Registration Rights Agreement is available from the
Company upon request at the address set forth below. All capitalized terms not otherwise defined herein shall have the meanings
ascribed thereto in the Registration Rights Agreement.

 

Certain legal consequences
arise from being named as a selling security holder in the Registration Statement and the related prospectus. Accordingly, holders
and beneficial owners of Registrable Securities are advised to consult their own securities law counsel regarding the consequences
of being named or not being named as a selling security holder in the Registration Statement and the related prospectus.

 

NOTICE

 

The undersigned beneficial
owner (the “Selling Securityholder”) of Registrable Securities hereby elects to include the Registrable Securities
owned by it in the Registration Statement.

 

The undersigned hereby
provides the following information to the Company and represents and warrants that such information is accurate:

 

QUESTIONNAIRE

 

1. Name: 

 

		(a)	Full Legal Name of Selling Securityholder
	 	 	 
	 	 	 

  

		(b)	Full Legal Name of Registered Holder (holder of record)
(if not the same as (a) above) through which Registrable Securities are held:
	 	 	 
	 	 	 

 

		(c)	If you are not a natural person, full Legal Name of Natural
Control Person (which means a natural person who directly or indirectly alone or with others has power to vote or dispose of the
securities covered by this Questionnaire):
	 	 	 
	 	 	 

 

    	 

    	 

    

 

2. Address for Notices to Selling
Securityholder:

 

	 
	 
	 
	Telephone:	 	   Fax:	 
	Email:	 	 
	Contact Person:	 	 

 

3. Broker-Dealer Status:

 

		(a)	Are you a broker-dealer?

 

Yes    ̈         No    ̈

 

		(b)	If “yes” to Section 3(a), did you receive your
Registrable Securities as compensation for investment banking services to the Company?

 

Yes    ̈         No    ̈

 

Note:    If
“no” to Section 3(b), the Commission’s staff has indicated that you should be identified as an underwriter in
the Registration Statement.

 

		(c)	Are you an affiliate of a broker-dealer?

 

Yes    ̈         No    ̈

 

		(d)	If you are an affiliate of a broker-dealer, do you certify
that you purchased the Registrable Securities in the ordinary course of business, and at the time of the purchase of the Registrable
Securities to be resold, you had no agreements or understandings, directly or indirectly, with any person to distribute the Registrable
Securities?

 

Yes    ̈         No    ̈

 

		Note:	If “no” to Section 3(d), the Commission’s
staff has indicated that you should be identified as an underwriter in the Registration Statement.

 

    	2

    	 

    

 

4. Beneficial Ownership of Securities of
the Company Owned by the Selling Securityholder:

 

Except as set forth below
in this Item 4, the undersigned is not the beneficial or registered owner of any securities of the Company.

 

			(a)          Please list the type (common stock,
warrants, etc.) and amount of all securities of the Company (including any Registrable Securities) beneficially owned1
by the Selling Securityholder:

 

		 	 
	 	 	 

 

5. Relationships with the Company:

 

Except as set forth below,
neither you nor (if you are a natural person) any member of your immediate family, nor (if you are not a natural person) any of
your affiliates2, officers, directors or principal equity holders (owners of 5% of more of the equity securities of
the undersigned) has held any position or office or has had any other material relationship with the Company (or its predecessors
or affiliates) during the past three years.

 

		 	State any exceptions here:
	 	 	 
	 	 	 
	 	 	 

 

 

		1	Beneficially Owned: 
A “beneficial owner” of a security includes any person who, directly or indirectly, through any contract, arrangement,
understanding, relationship or otherwise has or shares (i) voting power, including the power to direct
the voting of such security, or (ii) investment power, including the power to dispose of, or direct
the disposition of, such security.  In addition, a person is deemed to have “beneficial ownership” of a security
of which such person has the right to acquire beneficial ownership at any time within 60 days, including, but not limited
to, any right to acquire such security: (i) through the exercise of any option, warrant or right, (ii) through the conversion
of any security or (iii) pursuant to the power to revoke, or the automatic termination of, a trust, discretionary account
or similar arrangement.

 

It is possible that a security
may have more than one “beneficial owner,” such as a trust, with two co-trustees sharing voting power, and the settlor
or another third party having investment power, in which case each of the three would be the “beneficial owner” of
the securities in the trust.  The power to vote or direct the voting, or to invest or dispose of, or direct the investment
or disposition of, a security may be indirect and arise from legal, economic, contractual or other rights, and the determination
of beneficial ownership depends upon who ultimately possesses or shares the power to direct the voting or the disposition of the
security.

 

The final determination of the
existence of beneficial ownership depends upon the facts of each case.  You may, if you believe the facts warrant it, disclaim
beneficial ownership of securities that might otherwise be considered “beneficially owned” by you.

 

		2	Affiliate:  An “affiliate”
is a company or person that directly, or indirectly through one or more intermediaries, controls you, or is controlled by you,
or is under common control with you.

 

    	3

    	 

    

 

The undersigned agrees
to promptly notify the Company of any inaccuracies or changes in the information provided herein that may occur subsequent to the
date hereof at any time while the Registration Statement remains effective.

 

By signing below, the
undersigned consents to the disclosure of the information contained herein in its answers to Items 1 through 5 and the inclusion
of such information in the Registration Statement and the related prospectus and any amendments or supplements thereto. The undersigned
understands that such information will be relied upon by the Company in connection with the preparation or amendment of the Registration
Statement and the related prospectus and any amendments or supplements thereto.

 

IN WITNESS WHEREOF
the undersigned, by authority duly given, has caused this Selling Securityholder Notice and Questionnaire to be executed and delivered
either in person or by its duly authorized agent.

 

	BENEFICIAL OWNER (individual)	 	BENEFICIAL OWNER (entity)
	 	 	 
	 	 	 
	Signature	 	Name of Entity
	 	 	 
	 	 	 
	Print Name	 	Signature
	 	 	 
	 	 	Print Name: 	 
	Signature (if Joint Tenants or Tenants in Common)	 	 	 
	 	 	Title:	 

 

PLEASE E-MAIL OR FAX A COPY OF THE COMPLETED
AND EXECUTED SELLING SECURITYHOLDER NOTICE AND QUESTIONNAIRE, AND RETURN THE ORIGINAL BY OVERNIGHT MAIL, TO:

 

Gottbetter & Partners, LLP

488 Madison Avenue, 12th Floor

New York, NY 10022

Attention: Eleanor M. Osmanoff

Facsimile: (212) 400-6901

E-mail Address: emo@gottbetter.com

 

    	4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00225-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00225-of-00352.parquet"}]]